IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Pfizer eyes AstraZeneca for a reported $100 billion

1:55 AM MDT | April 22, 2014 | Natasha Alperowicz

UK press over the weekend said that Pfizer has made initial approaches to acquire AstraZeneca for £60 billion ($101 billion) in the world’s largest pharma acquisition. Both companies declined to comment on the report, which appears in The Sunday Times. A deal between Pfizer and AstraZeneca would create one of the top 10 companies globally by market value. AstraZeneca has rejected Pfizer’s overtures, according to the reports.   AstraZeneca is in a transitional phase, with sales and earnings expected to decline for the next couple of years...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa